メリーランド州における子宮内膜がんの臨床試験
メリーランド州内の拠点で、子宮内膜がんに関する22件の研究が参加者を募集しています。
メリーランド州内の都市
公式研究テキスト（英語）
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Walter Reed National Military Medical Center, Bethesda
- National Institutes of Health Clinical Center, Bethesda
- 他1件
被験者募集中第2相
全年齢 · 全性別 · 2026/10/02更新 · NCT05564377Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
被験者募集中第3相
18歳以上 · 女性 · 2026/10/02更新 · NCT07198074Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第2相
18歳〜72歳 · 全性別 · 2026/10/02更新 · NCT01174121A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Johns Hopkins University, Baltimore
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06172478A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Baltimore
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT05123482Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- Sinai Hospital, Baltimore
- William Kahlert Reg. Can. Ctr, Westminster
被験者募集中第3相
18歳以上 · 女性 · 2026/09/09更新 · NCT07166094DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Baltimore
- Research Site, Silver Spring
被験者募集中第3相
18歳以上 · 女性 · 2026/09/03更新 · NCT06989112FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center, Baltimore
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05919264A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- National Institutes of Health, Bethesda
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT05592626Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Maryland Oncology Hematology, Rockville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Maryland Oncology Hematology - Primary, Columbia
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/30更新 · NCT04657068Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Baltimore
- Research Site, Baltimore
- Research Site, Silver Spring
被験者募集中第3相
18歳以上 · 女性 · 2026/07/29更新 · NCT07044336Integrated Cancer Repository for Cancer Research
- Northwest Hospital, Randallstown
- William E. Kahlert Regional Cancer Center, Westminster
被験者募集中観察研究健康なボランティア歓迎
19歳〜110歳 · 全性別 · 2026/06/29更新 · NCT02012699Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Frederick Health Hospital, Frederick
被験者募集中観察研究
18歳以上 · 全性別 · 2026/06/29更新 · NCT07327489Vaginal Cuff Brachytherapy Fractionation Study
- University of Maryland Medical Center (UMMC), Baltimore
被験者募集中第3相
18歳以上 · 女性 · 2026/04/22更新 · NCT03785288Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第1/2相
18歳〜120歳 · 全性別 · 2026/04/09更新 · NCT06253494Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/11更新 · NCT03968406Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
- Maryland Oncology Hematology, P.A., Brandywine
被験者募集中第2相
18歳以上 · 女性 · 2025/12/24更新 · NCT06463028A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/11/04更新 · NCT05902988SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Bethesda
- Massive Bio SYNERGY-AI site, Silver Spring
- 他1件
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774BP1001-A in Patients With Advanced or Recurrent Solid Tumors
- Holy Cross Hospital, Silver Spring
被験者募集中第1相
18歳以上 · 全性別 · 2025/03/07更新 · NCT04196257Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- Maryland Oncology Hematology, P.A., Silver Spring
被験者募集中第2/3相
18歳以上 · 女性 · 2024/05/02更新 · NCT05797831ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。